US FDA lightens rules for diagnostics R&D that uses human specimens
This article was originally published in Clinica
Executive Summary
A new guidance under development at the US FDA will exempt diagnostics manufacturers from meeting patient-informed consent requirements when conducting studies that use only leftover human specimens that are not individually identifiable. The existing informed consent requirements "are bringing a halt to a class of very valuable research that can produce new diagnostic tests, without appreciably adding protection for human subjects," the agency said in a Federal Register notice on January 9.
You may also be interested in...
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Health And Wellness Weekly Trademarks Review: 16 April
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.